Opus Genetics is trading 5.04% down at $3.29 on October 26; no clear company-specific catalyst has been identified.
- The stock closed at $3.47 on October 23.
- A weekend investor-panel recap discussed the newly approved presbyopia treatment and pipeline but did not establish a reason for the decline.
- The broader market is higher; recent losses alone do not identify the cause.